tmem38b Antibody

What is TMEM38B and why is it significant in research?

TMEM38B, also known as TRIC-B (Trimeric intracellular cation channel type B), is an endoplasmic reticulum membrane monovalent cation-specific channel involved in the release of calcium (Ca²⁺) from intracellular stores. It represents one of two trimeric intracellular cation (TRIC) channel subtypes, with TMEM38B being expressed in most mammalian tissues, while TMEM38A is preferentially expressed in excitable tissues such as striated muscle and brain . TMEM38B is significant in research because TRIC-B deficiency causes bone disease due to defective Ca²⁺ release and signaling in bone cells, making it crucial for understanding calcium homeostasis mechanisms and related pathologies .

How do I select the appropriate TMEM38B antibody for my research?

When selecting a TMEM38B antibody, consider the following experimental parameters:

• Target species reactivity: Ensure the antibody has been validated for your species of interest. For example, antibody 19919-1-AP demonstrates reactivity with human, mouse, and rat samples, while 32251-1-AP has been tested primarily with human samples .

• Application compatibility: Determine which applications are necessary for your research. The table below summarizes application-specific dilutions for common TMEM38B antibodies:

• Validation data: Review the positive detection records in different cell lines. Antibody 19919-1-AP has been validated in HeLa and MCF-7 cells for WB, mouse testis and human kidney tissues for IHC, and HepG2 cells for IF/ICC .

What positive controls should I use when working with TMEM38B antibodies?

Based on validation data, recommended positive controls include:

• For Western blot: HeLa cells, MCF-7 cells, HepG2 cells, HEK-293 cells, and LNCaP cells have all shown positive detection with various TMEM38B antibodies .

• For immunohistochemistry: Mouse testis tissue and human kidney tissue have been successfully used with antibody 19919-1-AP with suggested antigen retrieval using TE buffer pH 9.0 (alternatively, citrate buffer pH 6.0) .

• For immunofluorescence: HepG2 cells have demonstrated positive detection with 19919-1-AP antibody .

What is the recommended protocol for Western blot detection of TMEM38B?

For optimal Western blot results with TMEM38B antibodies:

• Protein extraction: Use appropriate lysis buffers containing protease inhibitors (e.g., 13 mM benzamidine, 2 mM N-ethylmalemide, 5 mM EDTA, 1 mM PMSF, and 2 mM NaVO₃) to prevent protein degradation .

• Gel concentration: Use 12% SDS-PAGE gels for optimal resolution of TMEM38B, which has a calculated molecular weight of 33 kDa but typically appears at approximately 28 kDa on Western blots .

• Transfer conditions: Electrotransfer to PVDF membrane at 100V for 2 hours in transfer buffer containing 19 mM Tris-HCl, 192 mM glycine, and 20% (v/v) methanol .

• Blocking: Block membranes with 5% (w/v) milk in TBS-Tween for standard detection .

• Antibody dilution: For antibody 19919-1-AP, use a 1:500-1:1000 dilution; for 32251-1-AP, use a 1:1000-1:8000 dilution .

• Detection: The observed molecular weight is typically around 28 kDa, which differs slightly from the calculated molecular weight of 33 kDa (291 amino acids) .

What optimization strategies are recommended for immunohistochemistry with TMEM38B antibodies?

For optimal immunohistochemistry results:

• Antigen retrieval: Use TE buffer pH 9.0 as the primary recommended method. Alternatively, citrate buffer pH 6.0 can also be effective depending on tissue type and fixation method .

• Antibody dilution: Begin with a 1:50-1:500 dilution range for IHC applications using antibody 19919-1-AP, titrating to determine optimal concentration for your specific tissue .

• Tissue-specific considerations: Different tissue types may require adjustment of protocols. For instance, bone tissue studies involving TMEM38B might require decalcification steps before sectioning, which can affect epitope availability .

• Controls: Include both positive controls (mouse testis or human kidney tissue) and negative controls (isotype controls or tissues known to be negative for TMEM38B expression) .

How can I ensure specificity when using TMEM38B antibodies in complex tissue samples?

To ensure antibody specificity:

• Validation with knockout/knockdown models: When possible, include TMEM38B knockout or knockdown samples as negative controls. CRISPR/Cas9-mediated TMEM38B knockout models have been established and can serve as excellent specificity controls .

• Multiple antibody approach: Use antibodies raised against different epitopes of TMEM38B to confirm localization patterns.

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide to demonstrate binding specificity.

• Correlation with mRNA expression: Compare antibody detection patterns with TMEM38B mRNA expression data from tissues or cells of interest.

How can TMEM38B antibodies be applied in calcium signaling research?

TMEM38B plays a crucial role in calcium homeostasis as it functions in synchronization with calcium release from intracellular stores. Advanced applications include:

• Co-immunoprecipitation studies: Investigate interactions between TMEM38B and other components of calcium signaling pathways, such as ryanodine receptors or junctophilin proteins, which have been shown to work together to support efficient Ca²⁺ release in muscle cells .

• Live cell imaging: Combine immunofluorescence detection of TMEM38B with calcium imaging techniques to correlate TMEM38B localization with dynamic calcium signaling events.

• Subcellular fractionation: Use TMEM38B antibodies to track the distribution of this protein in different cellular compartments, particularly in the endoplasmic reticulum where it mainly functions.

• Calcium flux analysis: Compare calcium flux parameters in cells with varying levels of TMEM38B expression, using the antibody to confirm expression status.

What role does TMEM38B play in bone disease research, and how can antibodies facilitate these studies?

TMEM38B deficiency is associated with Osteogenesis imperfecta (OI) type XIV, a rare recessive bone disorder characterized by variable degrees of severity . Research applications include:

• Phenotypic characterization: Use TMEM38B antibodies to assess protein expression in patient-derived osteoblasts compared to controls.

• Pathway analysis: Investigate downstream effects of TMEM38B deficiency on collagen synthesis and post-translational modifications. Studies have shown that 3H-proline labeled collagen type I from TRIC-B knockout clones revealed faster migration of α(I) bands compared to controls, supporting reduced hydroxylation and glycosylation .

• Therapeutic development: Monitor TMEM38B expression levels in response to candidate therapeutic interventions aimed at rescuing cellular phenotypes associated with OI type XIV.

• Genetic modifier studies: Combine TMEM38B protein quantification with genetic analysis to identify potential modifiers of disease severity in OI patients.

How can TMEM38B antibodies be utilized in immunological research?

Recent research has identified TMEM38B as functionally linked to calcium/calmodulin-dependent serine/threonine kinase IV (CaMKIV) and CREB binding protein (CBP) in CD4+ T cells, affecting immune responses to vaccination . Advanced applications include:

• T cell activation studies: Investigate the role of TMEM38B in calcium-dependent T cell activation processes using flow cytometry and immunofluorescence approaches.

• Vaccine response research: Quantify TMEM38B expression levels in immune cells following vaccination to correlate with antibody production efficiency.

• Signaling pathway analysis: Use TMEM38B antibodies alongside phospho-specific antibodies to map calcium-dependent signaling cascades in immune cells.

• Transcriptional regulation: Combine chromatin immunoprecipitation techniques with TMEM38B detection to investigate its role in regulating gene expression during immune responses.

What are common issues encountered when using TMEM38B antibodies and how can they be addressed?

How do I interpret apparent molecular weight discrepancies for TMEM38B detection?

The calculated molecular weight of TMEM38B is 33 kDa (291 amino acids), but it is consistently observed at approximately 28 kDa in Western blots . This discrepancy may be due to:

• Post-translational modifications affecting mobility in SDS-PAGE

• Protein processing or cleavage events

• Secondary structure elements that persist during denaturation

When interpreting results, consider this established migration pattern and validate with appropriate controls to ensure correct identification of TMEM38B bands.

How can I optimize TMEM38B antibody performance for low-abundance detection?

For detecting low levels of TMEM38B:

• Signal amplification: Consider using enhanced chemiluminescence substrates for Western blots or tyramide signal amplification for immunohistochemistry and immunofluorescence.

• Sample enrichment: Perform subcellular fractionation to concentrate endoplasmic reticulum membranes where TMEM38B is primarily localized.

• Reduced background: Increase antibody specificity through additional blocking steps with 1-5% BSA or 2.5-5% milk, depending on the application .

• Extended exposure times: For Western blots, longer exposure times may be necessary while maintaining low background through optimized washing steps.

How are TMEM38B antibodies being employed in CRISPR/Cas9 genome editing validation?

TMEM38B antibodies serve as crucial validation tools in CRISPR/Cas9 genome editing experiments:

• Clone screening: Following CRISPR/Cas9 targeting of TMEM38B, Western blotting with specific antibodies is essential for confirming successful protein knockout in generated clones .

• Phenotype validation: Antibodies help correlate protein expression levels with observed phenotypes in CRISPR-engineered cell lines, providing validation of genotype-phenotype relationships.

• Off-target assessment: Multiple antibodies against different TMEM38B epitopes can help evaluate potential off-target effects by confirming complete absence of the protein.

• Rescue experiments: When reintroducing wild-type or mutant TMEM38B into knockout models, antibodies enable quantification of expression levels to ensure appropriate comparisons.

What novel methodological approaches are emerging for studying TMEM38B function?

Innovative techniques being developed include:

• Proximity labeling: Combining TMEM38B antibodies with proximity labeling techniques like BioID or APEX to identify novel interacting partners in the calcium signaling pathway.

• Super-resolution microscopy: Using fluorescently-labeled TMEM38B antibodies in techniques like STORM or PALM to visualize precise subcellular localization and potential clustering behavior.

• Single-cell analysis: Employing TMEM38B antibodies in single-cell protein profiling to understand cell-to-cell variability in expression and function.

• Multiparametric analysis: Developing multiplex antibody panels that include TMEM38B alongside other calcium channel components and signaling molecules to comprehensively assess pathway interactions.

How does TMEM38B function differ between tissue types, and how can antibodies help elucidate these differences?

While TMEM38B is widely expressed across tissues, its functional significance appears to vary:

• Comparative expression analysis: Using validated antibodies to quantify TMEM38B levels across different tissues and correlating with functional outcomes.

• Tissue-specific interactome mapping: Employing immunoprecipitation with TMEM38B antibodies followed by mass spectrometry to identify tissue-specific interaction partners.

• Developmental studies: Tracking TMEM38B expression patterns during development using immunohistochemistry to understand its role in tissue maturation, particularly in bone and lung tissues where deficiencies show critical phenotypes .

• Conditional knockout models: Validating tissue-specific knockout efficiency with antibodies to correlate with observed phenotypes and understand tissue-specific functions.